Kadcyla Storage, Preparation and Administration Recommendations

This article responds to your request for information on Kadcyla® (trastuzumab emtansine) and storage, preparation and administration recommendations.

Please refer to the locally approved storage information provided in the Kadcyla package insert or prescribing information. Any deviation from this information is considered off-label and any treatment decisions based on such deviations are the full responsibility of the prescribing physician.

Download article Download

Last updated August 15, 2023

Recommendations for Kadcyla storage temperature

Unopened vial

Kadcyla vials should be stored at 2°C to 8°C.[1]

If Kadcyla was inadvertantly stored outside of this temperature range, a stability assessment can be requested through medinfo.roche.com.

Reconstituted solution

Kadcyla vials reconstituted with sterile water for injection should be used immediately following reconstitution.1 If not used immediately, the reconstituted vials can be stored for up to 24 hours at 2°C to 8°C and must be discarded thereafter.

Do not freeze the reconstituted solution.

Infusion bag containing the diluted solution

The reconstituted Kadcyla solution diluted in 0.9% NaCl Injection, or 0.45% NaCl Injection, may be stored at 2°C to 8°C for up to 24 hours prior to use.[1]

Do not freeze the solution for infusion containing the reconstituted product.

Recommendation for Kadcyla light protection

Avoid exposing Kadcyla to direct daylight in all forms, including in the unopened vial, reconstituted solution, and diluted infusion bag.[2] Handling of Kadcyla in ambient light conditions is acceptable. Refer to the locally approved prescribing information for any additional storage recommendations.

Preparing Kadcyla IV solution

Recommended solutions for reconstitution and dilution

Kadcyla lyophilised powder should be reconstituted with sterile water according to the vial size and volume presented in Table 1.[1] The reconstituted solution should be further diluted with 0.9% NaCl or 0.45% NaCl.[1]

Table 1. Sterile water volume for reconstitution

For vial size 100mg vial and 160mg vial volume of sterile water is 5mL and 8mL

If Kadcyla was inadvertently reconstituted or diluted with a solution other than as described in the prescribing information, contact your local medical information service.

Precaution against using dextrose 5% solution

Roche recommends against reconstituting or diluting with dextrose (or glucose) 5% solution as it causes aggregation of the protein.[1]

Precaution against admixtures

Kadcyla should not be reconstituted, diluted, or mixed with other drugs.[1]

Compatibility of filters

Recommendation for the use of a PES filter

If Kadcyla was diluted in an infusion bag containing 0.9% NaCl solution, a 0.2 or 0.22 µm polyethersulfone (PES) in-line filter is required for administration to remove potential particulates that may occur in storage.[3]

While not required, a 0.2 or 0.22 µm PES in-line filter can be used during administration if Kadcyla was diluted in an infusion bag containing 0.45% NaCl solution.

Using other filters

Roche only recommends the use of a 0.2 or 0.22 µm PES in-line filter with Kadycla. The use of a different filter would be off-label and a clinical decision to be made by the physician after an analysis of the benefit-risk ratio.

Further studies have demonstrated compatibility of diluted Kadcyla solution with

  • 0.2 µm polysulphone (PSU) in-line filters (Terumo PB infusion line), [3] and
    • 0.2 µm nylon (positively charged Nylon Posidyne® membrane) in-line filters.[4]

      No data are available for the compatibility of diluted Kadcyla solutions with

      • polyvinyl chloride (PVC) in-line filters, or
        • in-line filters with a pore size of >0.22 µm.[2]



          1. Roche Internal Regulatory Report. Accessed 12 July 2023.
            1. Roche Internal Communications. Accessed 25 July 2023.
              1. Roche Internal Technical Report. Accessed 12 July 2023.
                1. Roche Internal Technical Report. Accessed 12 July 2023.

                  Welcome to Medically

                  The Roche Science Hub

                  This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

                  Not a healthcare professional? Browse:

                  This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

                  You are Leaving Medically

                  By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.